Cell & Gene: The Podcast
4 Keys to Allo in 2024 with Poseida Therapeutics' Kristin Yarema, Ph.D.
Jan 4, 2024
Poseida Therapeutics' CEO Kristin Yarema discusses the challenges of developing off-the-shelf therapies in CGT sector. She highlights the potential progress in allogeneic therapies by 2024. Topics include nanoparticle delivery, allogeneic T cell therapies, strategic investments, manufacturing scale up, and personal plans for 2024.
31:59
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Poseida Therapeutics is aiming to make significant progress in allogeneic therapies by 2024.
- Allogeneic T-cell therapies can meet the demand for more patients, are cost-effective, and offer volume and flexibility for patient access.
Deep dives
Poseida's Focus in Cell Therapy: Fully Allogeneic Approach
Poseida Therapeutics is focusing on a fully allogeneic approach in cell therapy. They initially worked on autologous CAR-T cell therapies but quickly shifted towards allogeneic approach. They now have three clinical stage programs, two in hematological malignancies and one in solid tumors. Their goal in 2024 is to execute and advance their pipeline in clinical development, while maintaining their unique culture at Poseida. They also emphasize the importance of their manufacturing capabilities, as they have their own clinical manufacturing facility to support all their programs.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
